Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE StudyBrian Bressler, Gerassimos J. Mantzaris, Jesse Siffledeen et al.|Journal of Crohn s and Colitis|2021Cited by 148
P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE studyAndrés Yarur, Brian Bressler, Gerassimos J. Mantzaris et al.|Journal of Crohn s and Colitis|2019Cited by 8
P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE studyBrian Bressler, Andrés Yarur, Gerassimos J. Mantzaris et al.|Journal of Crohn s and Colitis|2019Cited by 8
638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's DiseaseBrian Bressler, Gerassimos J. Mantzaris, Andrés Yarur et al.|The American Journal of Gastroenterology|2019Cited by 6
P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim resultsBrian Bressler, Dirk Demuth, A. Greenup et al.|Journal of Crohn s and Colitis|2018Cited by 4